Literature DB >> 9129996

Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo.

M Fukuzawa1, J Satoh, M Sagara, G Muto, Y Muto, S Nishimura, S Miyaguchi, X L Qiang, Y Sakata, T Nakazawa, F Ikehata, S Ohta, T Toyota.   

Abstract

It has been reported that angiotensin converting enzyme (ACE) inhibitors have beneficial effects on insulin resistance and congestive heart failure, in which elevations of serum tumor necrosis factor-alpha (TNF-alpha) level have been indicated. Therefore, in this study, we examined effect of ACE inhibitors on TNF-alpha production both in vitro and in vivo by using human blood mononuclear cells and mice, respectively. LPS (20 micrograms/ml)-induced in vitro TNF-alpha production, measured by bioassay and enzyme-linked immunosorbent assay, was significantly inhibited with captopril, delapril and cilazapril in a concentration of 10(-3) mol/l. A single, oral administration of captopril, delapril and cilazapril at more than 10-fold doses of common clinical use in man significantly inhibited LPS (2 mg/kg)-induced serum TNF-alpha activity in Balb/c mice. These results indicate that ACE inhibitors such as captopril, delapril and cilazapril have an inhibitory effect on TNF-alpha production not only in vitro as previously reported, but also in vivo, although relatively high concentrations and large doses were required in this study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129996     DOI: 10.1016/s0162-3109(96)00160-9

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  19 in total

1.  Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice.

Authors:  Y Inokuchi; T Morohashi; I Kawana; Y Nagashima; M Kihara; S Umemura
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 2.  Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

Authors:  A P Bolger; S D Anker
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 3.  Chronic heart failure and the immune system.

Authors:  Daniela Mari; Federica Di Berardino; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

4.  Intestinal intraepithelial lymphocyte derived angiotensin converting enzyme modulates epithelial cell apoptosis.

Authors:  B E Wildhaber; H Yang; E Q Haxhija; A U Spencer; D H Teitelbaum
Journal:  Apoptosis       Date:  2005-12       Impact factor: 4.677

5.  Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals.

Authors:  C Odaka; T Mizuochi
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 6.  Pathogenesis of neuroimmunologic diseases. Experimental models.

Authors:  C S Constantinescu; B Hilliard; T Fujioka; M K Bhopale; D Calida; A M Rostami
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

7.  In vitro and in vivo anti-inflammatory activity of 17-O-acetylacuminolide through the inhibition of cytokines, NF-κB translocation and IKKβ activity.

Authors:  Mouna Achoui; David Appleton; Mahmood Ameen Abdulla; Khalijah Awang; Mustafa Ali Mohd; Mohd Rais Mustafa
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

Review 8.  Role of tissue factor in atherothrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

Review 9.  Angiotensin II in inflammation, immunity and rheumatoid arthritis.

Authors:  Y Chang; W Wei
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

10.  Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on apoptotic changes in contralateral testis following unilateral testicular torsion.

Authors:  Gokhan Gokce; Hasan Karboga; Esin Yildiz; Semih Ayan; Yener Gultekin
Journal:  Int Urol Nephrol       Date:  2008-03-05       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.